Showing results (161-170 of 169) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 169 results.
Gut|May 19, 2019
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumabAnthony Dohan, Benoit Gallix, Boris Guiu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2020
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal CancerTakashi Kojima, Manish A Shah, Kei Muro, et al.
The New England Journal of Medicine|May 29, 2026
First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion MutationsCaicun Zhou, Laurent Greillier, Geoffrey Liu, et al.
Clinics and Research in Hepatology and Gastroenterology|February 21, 2022
MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancerEmeric Boisteau, Alexandra Lespagnol, Marie De Tayrac, et al.
The New England Journal of Medicine|November 27, 2024
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal CancerThierry Andre, Elena Elez, Eric Van Cutsem, et al.
BMC Cancer|August 27, 2017
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)Stefano Kim, Marine Jary, Thierry André, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2018
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III TrialThierry André, Dewi Vernerey, Laurent Mineur, et al.
The Lancet. Oncology|January 16, 2015
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih-Hsin Yang, Yi-Long Wu, Martin Schuler, et al.
Biomedicine Hub|February 10, 2021
Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in OncologyDenis Horgan, Gennaro Ciliberto, Pierfranco Conte, et al.
Pageof 17